{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-202879","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.508652+00:00","generated_at":"2026-05-31T08:42:13.594891+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M","bullets":["8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.","Gross proceeds ~$130M; net proceeds ~$121.7M after underwriting discounts and expenses.","Offering expected to close August 20, 2024; use proceeds for commercialization and vonoprazan clinical development.","Joint bookrunners: Evercore ISI, Stifel, Guggenheim; co-managers: H.C. Wainwright, Needham, Craig-Hallum."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-202879","json":"https://secwatch.observer/filing/0001193125-24-202879.json","markdown":"https://secwatch.observer/filing/0001193125-24-202879.md","text":"https://secwatch.observer/filing/0001193125-24-202879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524202879/0001193125-24-202879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524202879/d816262d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:42:13.594891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}